Generic Pharmaceutical Manufacturer
Active 2013–2026. The register lists this client once for every firm that files on its behalf; all 4 of its records are shown together here.
These two figures are not added together. A client that lobbies for itself reports its own spending, while firms it retains report what they were paid. Disclosure rules ask the in-house figure to include those payments, but filings do not always do so, and a filing gives no way to tell. Each is shown as reported.
| Year | Firm | Period | Amount | Doc |
|---|---|---|---|---|
| 2026 | AMNEAL PHARMACEUTICALS |
3rd Quarter (July 1 - Sep 30) 3rd Quarter - Report |
$210,000 | |
| 2026 | OGR |
3rd Quarter (July 1 - Sep 30) 3rd Quarter - Report |
$20,000 | |
| 2026 | AMNEAL PHARMACEUTICALS |
2nd Quarter (Apr 1 - June 30) 2nd Quarter - Report |
$190,000 | |
| 2026 | OGR |
2nd Quarter (Apr 1 - June 30) 2nd Quarter - Report |
$20,000 | |
| 2026 | AMNEAL PHARMACEUTICALS |
1st Quarter (Jan 1 - Mar 31) 1st Quarter - Report |
$190,000 | |
| 2026 | OGR |
1st Quarter (Jan 1 - Mar 31) 1st Quarter - Report |
$20,000 | |
| 2025 | AMNEAL PHARMACEUTICALS |
4th Quarter (Oct 1 - Dec 31) 4th Quarter - Report |
$340,000 | |
| 2025 | OGR |
4th Quarter (Oct 1 - Dec 31) 4th Quarter - Report |
$20,000 | |
| 2025 | AMNEAL PHARMACEUTICALS |
3rd Quarter (July 1 - Sep 30) 3rd Quarter - Report |
$310,000 | |
| 2025 | OGR |
3rd Quarter (July 1 - Sep 30) 3rd Quarter - Report |
$20,000 |
| Firm | Filings | Amount |
|---|---|---|
| AMNEAL PHARMACEUTICALS IN-HOUSE | 17 | $3,890,000 |
| BROWN RUDNICK LLP | 26 | $745,000 |
| FIERCE GOVERNMENT RELATIONS | 9 | $450,000 |
| OGR | 8 | $140,000 |
| Issue | Activities |
|---|---|
| Health Issues | 36 |
| Pharmacy | 22 |
| Budget/Appropriations | 8 |
| Manufacturing | 8 |
| Copyright/Patent/Trademark | 2 |
| Medicare/Medicaid | 2 |
| Trade (domestic/foreign) | 1 |